<DOC>
	<DOCNO>NCT02946138</DOCNO>
	<brief_summary>The aim research project ass efficacy toxicity hypofractionated carbon-ion radiotherapy concurrent granulocyte-macrophage colony-stimulating factor treatment hepatocellular carcinoma</brief_summary>
	<brief_title>Phase II Trial Carbon-ion Radiotherapy Combined With GM-CSF Treatment Hepatocellular Carcinoma</brief_title>
	<detailed_description>Golden E.B . et al.in 2015 report localized radiotherapy granulocyte-macrophage colony-stimulating factor ( GM-CSF ) produce objective abscopal response solid tumor metastasis . We hypothesize hypofractionated carbon-ion radiotherapy combine granulocyte-macrophage colony-stimulating factor ( GM-CSF ) might improve clinical response rate progression-free survival ( PFS ) hepatocellular carcinoma . The primary endpoint current phase II trial progression-free survival rate 2 year , secondary endpoint overall survival , safety toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1. histologically confirm hepatocellular carcinoma ( HCC ) clinical diagnosis HCC accord American association study liver diseases （AASLD）guidelines clinical diagnosis criterion base Alpha Fetoprotein （AFP ) , radiological image propose Liver Cancer Society , Chinese AntiCancer Association ; 2. clinically distant metastasis ; 3. tumor away gastrointestinal ( GI ) tract ( &gt; 1cm ) ; 4 . Child Push score A , technically unresectable , medically inoperable ; maximal tumor size le 10 cm ; 5. age ≥ 18 &lt; 80 year age ; 6 . Karnofsky Performance Score ≥ 70 ; 7 . No previous invasive cancer ( within 5 year HCC diagnosis ) except skin nonmelanoma cancer non muscle invasive bladder cancer ; Ability understand character individual consequence clinical trial ; 8 . Willing sign write informed consent ; Informed consent must sign enrollment trial ; 1 . Distant metastasis ( M1 ) ; 2. maximal tumor size 10 cm ; 3. tumor invade adjacent gastrointestine ( T4 ) ; 4 . Child push score B C ; 5 . Previous hepatic radiotherapy ; 6 . Severe systemic disorder ; 7 . Previous malignancy ( within 5 year ) except skin nonmelanoma cancer 3year disease free interval previous malignancy like situ cervix cancer non muscle invasive bladder cancer ; 8 . Non conformity radiotherapy dose distribution compare dose constraint ; 9 . Psychiatric disorder condition make unreliable informed consent ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>carbon-ion radiotherapy</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>immunotherapy</keyword>
</DOC>